Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

rEV 131

Drug Profile

rEV 131

Alternative Names: EV-131; rEV-131

Latest Information Update: 09 May 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evolutec
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Recombinant proteins
  • Mechanism of Action Histamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Allergic conjunctivitis; Allergic rhinitis; Asthma; Chronic obstructive pulmonary disease; Postoperative inflammation

Most Recent Events

  • 04 Dec 2006 A phase IIb trial of rEV 131 in Allergic rhinitis did not meet its primary endpoint
  • 22 Jun 2006 Phase-II clinical trials in Postoperative inflammation in USA (Ophthalmic)
  • 16 Jun 2006 Phase-II clinical trials in Allergic rhinitis in Canada (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top